BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30

• Biotech Bay

  Cellular Biomedicine Group Responds To Inquiries From Investors And The Scientific Community About Its Immuno-Oncology Cell Therapy Platform

  September 28, 2015

   · 

  6 min read
• Drug Development

  Boehringer Ingelheim Release: COPD: New Data Support Role Of Spiolto Respimat As 1st-Line Maintenance Therapy And Show Superiority Over LABA/ICS

  September 28, 2015

   · 

  5 min read
• Business

  Alnylam And Collaborators Report First-Ever Evidence That Patisiran Reduces Pathogenic, Misfolded Transthyretin (TTR) Monomers And Oligomers In TTR-Mediated Amyloidosis (ATTR Amyloidosis) Patients With Familial Amyloidotic Polyneuropathy (FAP)

  September 28, 2015

   · 

  1 min read
• BioMidwest

  Navidea Announces Addition To Major Indexes On Tel Aviv Stock Exchange

  September 28, 2015

   · 

  1 min read
• Business

  Biocept, Inc. Announces Participation In MultiPlan’s Networks

  September 28, 2015

   · 

  1 min read
• Drug Development

  Triphase Accelerator Announces Phase 1 Study Results With Marizomib In Combination With Pomalidomide And Dexamethasone In Patients With Relapsed And Refractory Multiple Myeloma

  September 28, 2015

   · 

  4 min read
• Drug Development

  Epizyme Announces Updated Tazemetostat Phase 1 Data Showing Clinical Activity In A Broader Range Of Adults With INI1-Negative And SMARCA4-Negative Solid Tumors

  September 28, 2015

   · 

  10 min read
• Policy

  Bristol-Myers Squibb Announces FDA Regulatory Filing Update For The Opdivo+Yervoy Regimen In Patients With Previously Untreated Advanced Melanoma

  September 28, 2015

   · 

  1 min read
• FDA

  Enanta Pharmaceuticals, Inc. Announces Approval Of VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) In Japan For The Treatment Of Genotype 1 Chronic Hepatitis C

  September 28, 2015

   · 

  9 min read
• FDA

  Teva Announces Approval Of COPAXONE In Japan For The Prevention Of Relapse Of Multiple Sclerosis

  September 28, 2015

   · 

  6 min read